Barrigel™ Rectal Spacer for Prostate Radiation Therapy
PHYSICIAN-CONTROLLED SPACING1-4
CONTROL
MATTERS
PLACEMENT YOU CAN PLAN ON1-5
Barrigel™ rectal spacer is the only sculptable spacer that gives you control over the shape and placement of the implant.1-4,6 Physician-controlled spacing provides confidence in achieving safe, symmetric and stable space.1-2**

Quick Resources
Barrigel Physician Testimonials*
Barrigel Physician Testimonials*
Barrigel Physician Testimonials*
DEMONSTRATED SAFETY1
BUILD STABLE
SPACE1-2,4
Pivotal Trial Results1
Proven superior
in the reduction of acute grade 2+ GI toxicity compared to control
Zero
Barrigel spacer-related adverse events
3-Year Results
(ESTRO 2026 Abstract)7
Continued reduction
in long-term toxicities
Zero
long-term Grade 2+GI toxicities compared to control.
ACHIEVE CONSISTENT COVERAGE2
SYMMETRY
MATTERS

BUILD STABLE SPACE1-2,4
BUILD STABLE
SPACE1-2,4
Barrigel maintains stable rectal spacing during resorption.2† Even as Barrigel spacer gradually resorbs, shape and separation are maintained, on average, through 3 months.1-2 There were zero reports of implant migration in the Barrigel Pivotal Trial.2

Results may vary.

Results may vary.
References
**In a secondary analysis of data from the Barrigel pivotal trial, 95.6% of implants were found to be symmetric using the methodology from Fischer-Valuck BW et al. Pract Radiat Oncol (2017).
†On average through 3 months
-
Mariados NF, Orio PF III, King MT et al. JAMA Oncol (2023).‡§
-
Svatos M, Chell E, King MT et al. Med Phys (2024).‡§
-
Williams J, Mc Millan K, Chao M et al. J Med Imag Radiat Sci (2022).§
-
Gejerman G, Goldstein MM, Chao M et al. Pract Radiat Oncol (2023).§
-
King MT, Svatos M, Orio PF III et al. Pract Radiat Oncol (2023).‡§
-
Data on file. As of 7/01/2025.
-
King M, Chao M et al. Prospective Randomized Controlled Trial of Hyaluronic Acid Spacer for Hypofractionated Prostate Radiation Therapy: 3-Year Results. Presented at: European Society for Radiotherapy and Oncology 2026 Annual Congress; May 2026; Stockholm, Sweden. Proffered Paper 3623.‡§
‡ Study sponsored by Palette Life Sciences, now part of Teleflex.
§ One or more of the authors are paid consultants of Teleflex.
-